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ABSTRACT
Introduction: Newborn screening allows the screening of diseases that are still in 
the asymptomatic period and whose early diagnosis and treatment are associated 
with reduced infant morbidity and mortality. The aim of this study was to evaluate the 
public National Newborn Screening Program in the municipality of Carazinho, state 
of Rio Grande do Sul (RS), Brazil.
Methods: This was a population-based, retrospective, descriptive study. We collected 
and transcribed data from a database of the Carazinho municipal laboratory, which 
is affiliated with the referral center for newborn screening in RS. The records of all 
individuals undergoing newborn screening from 2005 to 2010 were reviewed, and 
information was collected on the program coverage, time elapsed between birth and 
screening (first collection), and test results.
Results: The program had a coverage of 75.5%. One suspected case of phenylketonuria, 
three suspected cases of congenital hypothyroidism and no suspected cases of 
hemoglobinopathy were identified. In addition, there were 18 positive results for 
hemoglobin S heterozygosity, five for hemoglobin D heterozygosity, two for hemoglobin 
C heterozygosity, and one for a rare variant hemoglobin. When analyzing the 
newborn’s age at the time of blood collection, it was observed that 63.1% were within 
the recommended age range.
Conclusions: Our findings suggest the need for optimization of public newborn 
screening in the evaluated municipality. The strategies to be adopted should include 
education of the population and especially of managers and health professionals 
about the importance of newborn screening.
Keywords: Newborn screening; public health; mass screening
Newborn screening, also known as the heel-prick test because blood is 
collected from the newborn’s heel, includes a series of laboratory tests that 
aim to identify certain genetic diseases in the asymptomatic stage. The first 
blood sample should preferably be collected between the third and fifth day 
of life1. This is an important strategy to reduce infant morbidity and mortality 
through early detection of treatable diseases that may lead to severe clinical 
presentations2,3. Therefore, the adoption of preventive actions, as early 
diagnosis and treatment, can change the natural history of diseases detected 
by newborn screening4. The selection of diseases for inclusion in a newborn 
screening program is mainly based on three criteria: a) disease detection 
should be feasible in the pre-symptomatic period; b) the disease should be 
treatable; and c) there should be the possibility of starting treatment at early 
disease stages5.
Over the past two decades, the introduction of tandem mass spectrometry 
(MS/MS) has substantially expanded the number of disorders that can be 
detected in dried blood spot on filter paper. This test allows the simultaneous 
detection of more than 30 diseases, including organic acidemias and disorders 
of fatty acid metabolism5. Congenital hypothyroidism (CH) is the most widely 
screened disease in newborn screening programs worldwide6.
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In Brazil, a newborn screening program was 
initiated in the city of São Paulo in the 1970s by the 
pediatrician Benjamim Schmidt, with screening tests 
for phenylketonuria in the Association of Parents and 
Friends of Special Need Individuals (Associação de 
Pais e Amigos dos Excepcionais, APAE). In 2001, the 
Brazilian Ministry of Health implemented the National 
Newborn Screening Program (Programa Nacional de 
Triagem Neonatal, PNTN) through Regulation No. 
822 of June 06, 2001. This regulation established a 
series of tests for early disease screening, diagnostic 
confirmation, treatment, follow-up, and database 
recording, with an intended coverage of 100% live 
births. The availability of tests was defined for each 
Brazilian state based on the preexisting coverage and 
infrastructure of health care services. The program 
was divided into three screening phases, as follows: 
Phase I – phenylketonuria and CH; Phase II – 
phenylketonuria, CH, and hemoglobinopathies; and 
Phase III – phenylketonuria, CH, hemoglobinopathies, 
and cystic fibrosis7.
Later, Regulation No. 2,829 of December 14, 
2012, included newborn screening for congenital 
adrenal hyperplasia and biotinidase deficiency within 
the scope of the program, encompassing all states 
in a single category8. Currently, there are 30 referral 
centers for newborn screening (Serviços de Referência 
em Triagem Neonatal, SRTN) in the 27 Brazilian 
federative units, which serve 17,854 collection stations9. 
Expanded screening, which enables the detection of 
up to 30 diseases, is provided by the public health 
system only in the Federal District and is available as 
a pilot program in the state of Minas Gerais6.
Newborn screening in the state of Rio Grande do 
Sul (RS) began in the late 1980s as isolated initiatives 
in public hospital laboratories. It was only in 1994 
that the state government began to offer screening 
tests in partnership with Universidade Federal do 
Rio Grande do Sul (UFRGS) and UFRGS School 
of Pharmacy. Currently, the referral institution for 
newborn screening in the state of RS is Hospital 
Materno Infantil Presidente Vargas, where the SRTN 
operates. Like most centers in other states, this SRTN 
is equipped with its own laboratory, which performs 
more than 60,000 laboratory tests per month. In 2015, 
the SRTN served 1,307 collection stations throughout 
the 497 municipalities that provide newborn screening 
as a public health service in the state1.
First introduced in the United States in 1963, 
newborn screening is celebrating its 55th anniversary 
in 2018, coinciding with the 17th anniversary of the 
PNTN in Brazil. Therefore, an update on results is 
warranted to reflect the current state of newborn 
screening practice at the municipal level. The present 
study aimed to describe and evaluate newborn 
screening provided as a public health service in a 
municipality of the state of RS from 2005 to 2010.
METHODS
This population-based, observational, descriptive 
study with retrospective data collection was conducted 
in Carazinho, a municipality located in central-northern 
RS. In 2010, the population was 59,317 inhabitants10, 
and the municipality was served by the 6th Regional 
Health District of Rio Grande do Sul.
The study was approved and data collection was 
authorized by the Municipal Health Department in 
Carazinho. Data were collected from the database of 
the Carazinho municipal laboratory, which contains 
all the results of newborn screening tests performed 
by the SRTN in the municipality.
The records of all individuals undergoing newborn 
screening from 2005 to 2010 were reviewed for 
information on the time elapsed between birth and 
screening and on the results of screening tests. 
During the study period, RS was in the Phase II of 
PNTN, i.e., screening for phenylketonuria, CH, and 
hemoglobinopathies.
The coverage of the screening program in 
Carazinho was determined based on data from the 
IT Department of the Brazilian Unified Health System 
(DATASUS), considering all live births occurring in 
the municipality from 2005 to 2010. Coverage was 
calculated as the number of tests performed multiplied 
by 100 and divided by the number of live births.
For age at collection of biological samples, we 
considered the period recommended before the 
Regulation No. 2,829 of 2012 became effective, 
i.e., blood collection up to the seventh day of life. 
After 2012, the ideal collection period was shortened 
to the fifth day of life, and delayed collection was 
defined as that performed after the sixth day of life.
Of note, regarding the screened diseases, we 
describe the results of screening tests, and not 
of confirmatory tests, as the latter were not made 
available to the researchers.
RESULTS
From 2005 to 2010, 4,647 children were born in 
Carazinho. Of these, 3,417 (75.5%) were screened for 
phenylketonuria and CH in the public health system. 
However, 3,410 (73.4%) children were screened for 
hemoglobinopathies because they had undergone 
transfusion procedures before collection. The results 
of the seven children screened for hemoglobinopathies 
30 days after transfusion were not available at the 
time of data collection.
One suspected case of phenylketonuria and 
three suspected cases of CH were identified by 
laboratory analysis. There was no suspected case 
of hemoglobinopathy. In 18 cases, the results were 
positive for hemoglobin S heterozygosity, in five cases 
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for hemoglobin D heterozygosity, in two cases for 
hemoglobin C heterozygosity, and in one case for a 
rare variant hemoglobin.
Table 1 shows the newborn’s age at the time of 
blood collection stratified according to the collection 
period recommended by the Brazilian Ministry of 
Health.
DISCUSSION
Newborn screening, which was consolidated in 
Brazil through the PNTN, aims to improve the quality 
of life of individuals affected by several diseases 
through early diagnosis. The introduction of the PNTN 
has been associated with a marked reduction in 
infant mortality over the years4. However, the proper 
implementation of this program still faces difficulties, 
such as the lack of financial resources, mobilization 
of the target audience and awareness of health 
managers, and inappropriate time of collection or 
transportation. This becomes evident from the wide 
variation and discrepancy across Brazilian states in 
the results reported in the “Situation Diagnosis of 
the PNTN”, a survey conducted together with the 
Brazilian Ministry of Health in 201311.
Estimating the coverage of newborn screening is 
extremely important because it enables to analyze 
the percentage of children who were not screened, 
thereby allowing a partial analysis of the situation of the 
program under study. After the PNTN was established 
in 2001, there was an increase in the coverage of 
newborn screening in Brazil, reaching 80% in 2005, 
although it was heterogeneously distributed among 
states2. Currently, all Brazilian states and the Federal 
District have SRTNs and collection stations, the latter 
being usually located in primary health care units. 
In 2013, the exact number of tests performed and 
patients receiving follow-up was unknown by state 
managers and by the Brazilian Ministry of Health11. 
In 2016, according to the Brazilian Ministry of Health, 
the coverage of public newborn screening was 83.6% 
in Brazil12. In 2015, the coverage reached 83% in 
RS1,2. In the municipality of Carazinho, according to 
data from a master’s degree thesis, the coverage 
was 72.2% in 200613.
A newborn screening program is successful when 
there is government priority and funding, population 
education and acceptance, engagement of health 
care professionals, and government participation in 
the implementation of the program11. The municipality 
under study did not achieve the ideal coverage of 
public screening recommended by the Brazilian 
Ministry of Health. However, it is important to point out 
that coverage rates may have been underestimated, 
since tests may have been performed in private 
health facilities and, therefore, were not available 
for analysis.
The low coverage of newborn screening in Brazil 
is justified by various reasons, the most important of 
which are the tests performed in the private health 
system, poor dissemination of the PNTN, and cultural 
traits that neglect the importance of newborn screening. 
The extent of this coverage is known to be directly 
influenced by cultural and socioeconomic factors, 
as demonstrated in more developed countries like 
Spain, France, Italy, Austria, Russia, New Zealand, 
Scotland, and Australia, where coverage is close to 
or reaches 100%2.
According to some authors, it is essential to 
collect blood samples for newborn screening before 
hospital discharge in order to achieve a satisfactory 
coverage and to meet the ideal collection period14. 
However, it would be necessary, in the case of 
phenylketonuria, for example, to reduce cutoff 
points for normal and abnormal phenylalanine levels 
in order to identify children who had low protein 
intake through breastfeeding in their first hours of 
life. The unfavorable aspect of this strategy is that it 
would increase the number of false positive cases, 
which may increase costs because of the need for 
additional tests, also increasing the family’s anxiety. 
Also worthy of note is that blood collection through 
the Brazilian Unified Health System (Sistema Único 
de Saúde) and the PNTN should be performed in 
an outpatient setting, except in special cases such 
as preterm infants and those with prolonged stay in 
the neonatal intensive care unit.
The PNTN has some guidelines and standards 
for the period of blood sample collection for newborn 
screening. The ideal collection period was up to the 
seventh day of life before Regulation No. 2,829 of 
2012, which was shortened to the fifth day of life after 
the publication of this regulation. In 2015, 2.5 million 
newborns were screened in the PNTN. Of these, 
Table 1: Newborn’s age at blood collection for newborn screening (2005-2010).
Newborn’s age % n
< 7 days of life* 63.1 2.157
7-30 days of life* 34.9 1.192
> 30 days of life* 2.0 68
*Collection period recommended by the Brazilian Ministry of Health before Regulation no. 2.829 of 2012.
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only 53% were tested before the fifth day of life11. 
In Carazinho, most children were screened within the 
ideal period recommended by the guidelines in effect 
at the time of the study. It is worth noting that this 
period may vary among different countries, since it 
depends of the sensitivity of diagnostic technologies4 
and needs inherent in the diseases included within 
the scope of the screening program.
Regarding the incidence of the screened diseases, 
the reported numbers vary worldwide. For example, 
the worldwide incidence of phenylketonuria, a rare 
genetic disease in which a metabolic defect leads 
to the accumulation of blood phenylalanine, is 
estimated at 1 in approximately 10,000 newborns5, 
and varies among countries and regions because 
of differences in rates of consanguinity15. In Brazil, 
the incidence of phenylketonuria was estimated at 
1:15,839 newborns in 2001 and 1:24,780 newborns 
in 200216. In 1996, Jardim et al. estimated that 1 in 
every 12,500 live births had phenylketonuria in RS17. 
In this state, screening (first sample) is performed 
through quantitative dosing of blood phenylalanine 
using filter paper, and abnormal results are confirmed 
by more specific tests (second sample) performed 
using serum, whole blood or urine samples1.
Similar findings have been reported for CH, 
the most common congenital endocrine disorder, 
whose incidence has been found to vary among 
ethnic groups, with lower prevalence rates in African 
Americans than in Hispanics. Moreover, women 
are known to be more affected than men (at a 2:1 
ratio), as well as children with Down syndrome. CH 
is caused by failure of the thyroid gland to produce 
adequate amounts of thyroid hormones, resulting 
in a generalized reduction in metabolic processes4. 
Currently, CH has a worldwide incidence of 1 in 
approximately 3,500 live births4. A similar incidence 
has been observed in Brazil, where the estimated 
rates range from 1:2,595 to 1:4,795 live births1,18. In the 
PNTN, CH is screened by dosing thyroid-stimulating 
hormone (TSH) with filter paper. CH is confirmed if 
serum TSH levels are above 20 mUI/L. Reduced 
levels of total T4, free T3 and free T4 confirm the 
diagnosis of primary defect in the thyroid gland1.
As for hemoglobinopathies, these are the most 
prevalent genetic diseases in humans, and the 
most frequent and clinically significant variants are 
those affecting hemoglobin S and C. This disease is 
characterized by a structural defect in the beta chain of 
hemoglobin leading to the formation of sickle-shaped 
red blood cells. Data from the literature show that 
sickle cell anemia is 10 to 30 times more common 
than phenylketonuria, especially in regions where the 
population is of mixed race, like the Brazilian state 
of Bahia, where the incidence of sickle cell anemia 
is 1:650 live births19,20.
The heel-prick test is economically feasible for 
the government, leading to a reduction in the number 
of disabled individuals and reducing expenditures 
on benefits to people with disabilities21. This study 
highlights the complexity of the PNTN, resulting from 
the vastness of the Brazilian territory and cultural 
diversity in the country, with an urgent need to 
improve the program. In conclusion, future strategies 
should focus on improving indicators and enabling 
the proper development of the program, including the 
following aspects: population awareness; education 
of managers from the three government spheres and 
of health professionals about the importance of the 
program; and consequent enhancement of actions 
and results for the benefit of the entire Brazilian 
population.
This study was performed at Universidade 
Luterana do Brasil (Carazinho, southern Brazil).
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